ID   BRCA2_HUMAN             Reviewed;        3418 AA.
AC   P51587; O00183; O15008; Q13879; Q5TBJ7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-NOV-2015, sequence version 3.
DT   15-FEB-2017, entry version 192.
DE   RecName: Full=Breast cancer type 2 susceptibility protein;
DE   AltName: Full=Fanconi anemia group D1 protein;
GN   Name=BRCA2; Synonyms=FACD, FANCD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8524414; DOI=10.1038/378789a0;
RA   Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J.,
RA   Collins N., Gregory S., Gumbs C., Micklem G., Barfoot R., Hamoudi R.,
RA   Patel S., Rice C., Biggs P., Hashim Y., Smith A., Connor F.,
RA   Arason A., Gudmundsson J., Ficenec D., Kelsell D., Ford D., Tonin P.,
RA   Bishop D.T., Spurr N.K., Ponder B.A.J., Eeles R., Peto J., Devilee P.,
RA   Cornelisse C., Lynch H., Narod S., Lenoir G., Egilsson V.,
RA   Barkadottir R.B., Easton D.F., Bentley D.R., Futreal P.A.,
RA   Ashworth A., Stratton M.R.;
RT   "Identification of the breast cancer susceptibility gene BRCA2.";
RL   Nature 378:789-792(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS HIS-372 AND PHE-599.
RX   PubMed=8589730; DOI=10.1038/ng0396-333;
RA   Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D.,
RA   Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D.,
RA   Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T.,
RA   Dumont M., Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P.,
RA   Kehrer R., Leblanc J.-F., Mitchell J.T., McArthur-Morrison J.,
RA   Nguyen K., Peng Y., Samson C., Schroeder M., Snyder S.C., Steele L.,
RA   Stringfellow M., Stroup C., Swedlund B., Swensen J., Teng D.,
RA   Thomas A., Tran T., Tran T., Tranchant M., Weaver-Feldhaus J.,
RA   Wong A.K.C., Shizuya H., Eyfjord J.E., Cannon-Albright L., Labrie F.,
RA   Skolnick M.H., Weber B., Kamb A., Goldar D.E.;
RT   "The complete BRCA2 gene and mutations in chromosome 13q-linked
RT   kindreds.";
RL   Nat. Genet. 12:333-337(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-289; GLN-322;
RP   HIS-372; VAL-784; SER-929; PHE-976; ILE-987; ASP-991; ASN-1561;
RP   LYS-1880; MET-1915; PHE-2138; ARG-2162; ARG-2440; VAL-2466; THR-2490;
RP   PRO-2835; ALA-2856; PHE-2944; THR-2951; ILE-3244 AND VAL-3412.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   INVOLVEMENT IN PNCA2.
RX   PubMed=9140390; DOI=10.1038/ng0597-17;
RA   Ozcelik H., Schmocker B., Di Nicola N., Shi X.H., Langer B., Moore M.,
RA   Taylor B.R., Narod S.A., Darlington G., Andrulis I.L., Gallinger S.,
RA   Redston M.;
RT   "Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic
RT   cancer patients.";
RL   Nat. Genet. 16:17-18(1997).
RN   [6]
RP   INTERACTION WITH SEM1.
RX   PubMed=10373512; DOI=10.1128/MCB.19.7.4633;
RA   Marston N.J., Richards W.J., Hughes D., Bertwistle D., Marshall C.J.,
RA   Ashworth A.;
RT   "Interaction between the product of the breast cancer susceptibility
RT   gene BRCA2 and DSS1, a protein functionally conserved from yeast to
RT   mammals.";
RL   Mol. Cell. Biol. 19:4633-4642(1999).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH FANCD2.
RX   PubMed=15115758; DOI=10.1093/hmg/ddh135;
RA   Hussain S., Wilson J.B., Medhurst A.L., Hejna J., Witt E., Ananth S.,
RA   Davies A., Masson J.-Y., Moses R., West S.C., de Winter J.P.,
RA   Ashworth A., Jones N.J., Mathew C.G.;
RT   "Direct interaction of FANCD2 with BRCA2 in DNA damage response
RT   pathways.";
RL   Hum. Mol. Genet. 13:1241-1248(2004).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH FANCD2.
RX   PubMed=15199141; DOI=10.1128/MCB.24.13.5850-5862.2004;
RA   Wang X.Z., Andreassen P.R., D'Andrea A.D.;
RT   "Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1
RT   in chromatin.";
RL   Mol. Cell. Biol. 24:5850-5862(2004).
RN   [9]
RP   UBIQUITINATION, DEUBIQUITINATION, AND INTERACTION WITH USP11.
RX   PubMed=15314155; DOI=10.1128/MCB.24.17.7444-7455.2004;
RA   Schoenfeld A.R., Apgar S., Dolios G., Wang R., Aaronson S.A.;
RT   "BRCA2 is ubiquitinated in vivo and interacts with USP11, a
RT   deubiquitinating enzyme that exhibits prosurvival function in the
RT   cellular response to DNA damage.";
RL   Mol. Cell. Biol. 24:7444-7455(2004).
RN   [10]
RP   INVOLVEMENT IN GLM3.
RX   PubMed=15689453; DOI=10.1136/jmg.2004.022673;
RG   The famillial Wilms tumor collaboration;
RA   Reid S., Renwick A., Seal S., Baskcomb L., Barfoot R., Jayatilake H.,
RA   Pritchard-Jones K., Stratton M.R., Ridolfi-Luethy A., Rahman N.;
RT   "Biallelic BRCA2 mutations are associated with multiple malignancies
RT   in childhood including familial Wilms tumour.";
RL   J. Med. Genet. 42:147-151(2005).
RN   [11]
RP   FUNCTION.
RX   PubMed=15671039; DOI=10.1074/jbc.M414669200;
RA   Ohashi A., Zdzienicka M.Z., Chen J., Couch F.J.;
RT   "FANCD2 functions independently of BRCA2 and RAD51 associated
RT   homologous recombination in response to DNA damage.";
RL   J. Biol. Chem. 280:14877-14883(2005).
RN   [12]
RP   PHOSPHORYLATION AT SER-3291 BY CDK2, INTERACTION WITH RAD51, AND
RP   MUTAGENESIS OF SER-3291.
RX   PubMed=15800615; DOI=10.1038/nature03404;
RA   Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., West S.C.;
RT   "CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for
RT   recombinational repair.";
RL   Nature 434:598-604(2005).
RN   [13]
RP   INTERACTION WITH WDR16.
RX   PubMed=15967112; DOI=10.1593/neo.04544;
RA   Silva F.P., Hamamoto R., Nakamura Y., Furukawa Y.;
RT   "WDRPUH, a novel WD-repeat-containing protein, is highly expressed in
RT   human hepatocellular carcinoma and involved in cell proliferation.";
RL   Neoplasia 7:348-355(2005).
RN   [14]
RP   INTERACTION WITH PALB2, AND CHARACTERIZATION OF VARIANTS BC ARG-25;
RP   CYS-31 AND ARG-31.
RX   PubMed=16793542; DOI=10.1016/j.molcel.2006.05.022;
RA   Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X.,
RA   Jasin M., Couch F.J., Livingston D.M.;
RT   "Control of BRCA2 cellular and clinical functions by a nuclear
RT   partner, PALB2.";
RL   Mol. Cell 22:719-729(2006).
RN   [15]
RP   INTERACTION WITH SEM1.
RX   PubMed=16205630; DOI=10.1038/sj.onc.1209153;
RA   Li J., Zou C., Bai Y., Wazer D.E., Band V., Gao Q.;
RT   "DSS1 is required for the stability of BRCA2.";
RL   Oncogene 25:1186-1194(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-755, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   INTERACTION WITH FANCD2; FANCG AND XRCC3.
RX   PubMed=18212739; DOI=10.1038/sj.onc.1211034;
RA   Wilson J.B., Yamamoto K., Marriott A.S., Hussain S., Sung P.,
RA   Hoatlin M.E., Mathew C.G., Takata M., Thompson L.H., Kupfer G.M.,
RA   Jones N.J.;
RT   "FANCG promotes formation of a newly identified protein complex
RT   containing BRCA2, FANCD2 and XRCC3.";
RL   Oncogene 27:3641-3652(2008).
RN   [18]
RP   FUNCTION IN RAD51-DEPENDENT DNA REPAIR, PHOSPHORYLATION AT THR-3387 BY
RP   CHEK1 AND CHEK2, MUTAGENESIS OF THR-3387, AND INTERACTION WITH RAD51.
RX   PubMed=18317453; DOI=10.1038/onc.2008.17;
RA   Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z.,
RA   Hasty P.E., Stambrook P.J.;
RT   "The checkpoint kinases Chk1 and Chk2 regulate the functional
RT   associations between hBRCA2 and Rad51 in response to DNA damage.";
RL   Oncogene 27:3977-3985(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN A BRCA
RP   COMPLEX WITH BRCA1 AND PALB2.
RX   PubMed=19369211; DOI=10.1073/pnas.0811159106;
RA   Sy S.M., Huen M.S., Chen J.;
RT   "PALB2 is an integral component of the BRCA complex required for
RT   homologous recombination repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:7155-7160(2009).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH RAD51.
RX   PubMed=20729859; DOI=10.1038/nsmb.1904;
RA   Liu J., Doty T., Gibson B., Heyer W.D.;
RT   "Human BRCA2 protein promotes RAD51 filament formation on RPA-covered
RT   single-stranded DNA.";
RL   Nat. Struct. Mol. Biol. 17:1260-1262(2010).
RN   [21]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=20729858; DOI=10.1038/nsmb.1905;
RA   Thorslund T., McIlwraith M.J., Compton S.A., Lekomtsev S.,
RA   Petronczki M., Griffith J.D., West S.C.;
RT   "The breast cancer tumor suppressor BRCA2 promotes the specific
RT   targeting of RAD51 to single-stranded DNA.";
RL   Nat. Struct. Mol. Biol. 17:1263-1265(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH
RP   RAD51 AND DMC1.
RX   PubMed=20729832; DOI=10.1038/nature09399;
RA   Jensen R.B., Carreira A., Kowalczykowski S.C.;
RT   "Purified human BRCA2 stimulates RAD51-mediated recombination.";
RL   Nature 467:678-683(2010).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH ROCK2 AND NPM1.
RX   PubMed=21084279; DOI=10.1158/0008-5472.CAN-10-0030;
RA   Wang H.F., Takenaka K., Nakanishi A., Miki Y.;
RT   "BRCA2 and nucleophosmin coregulate centrosome amplification and form
RT   a complex with the Rho effector kinase ROCK2.";
RL   Cancer Res. 71:68-77(2011).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21276791; DOI=10.1016/j.yexcr.2011.01.021;
RA   Cappelli E., Townsend S., Griffin C., Thacker J.;
RT   "Homologous recombination proteins are associated with centrosomes and
RT   are required for mitotic stability.";
RL   Exp. Cell Res. 317:1203-1213(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-445; SER-492;
RP   SER-1970; THR-2035; SER-2095 AND SER-3319, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   INTERACTION WITH SEM1, CHARACTERIZATION OF VARIANT BC HIS-2723,
RP   MUTAGENESIS OF TRP-2725, NUCLEAR EXPORT SIGNAL, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=24013206; DOI=10.1038/nsmb.2666;
RA   Jeyasekharan A.D., Liu Y., Hattori H., Pisupati V., Jonsdottir A.B.,
RA   Rajendra E., Lee M., Sundaramoorthy E., Schlachter S., Kaminski C.F.,
RA   Ofir-Rosenfeld Y., Sato K., Savill J., Ayoub N., Venkitaraman A.R.;
RT   "A cancer-associated BRCA2 mutation reveals masked nuclear export
RT   signals controlling localization.";
RL   Nat. Struct. Mol. Biol. 20:1191-1198(2013).
RN   [27]
RP   INTERACTION WITH PALB2, AND IDENTIFICATION IN A PALB2-CONTAINING HR
RP   COMPLEX.
RX   PubMed=24141787; DOI=10.1038/onc.2013.421;
RA   Park J.Y., Singh T.R., Nassar N., Zhang F., Freund M., Hanenberg H.,
RA   Meetei A.R., Andreassen P.R.;
RT   "Breast cancer-associated missense mutants of the PALB2 WD40 domain,
RT   which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.";
RL   Oncogene 33:4803-4812(2014).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH POLH.
RX   PubMed=24485656; DOI=10.1016/j.celrep.2014.01.009;
RA   Buisson R., Niraj J., Pauty J., Maity R., Zhao W., Coulombe Y.,
RA   Sung P., Masson J.Y.;
RT   "Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in
RT   recombination-associated DNA synthesis at blocked replication forks.";
RL   Cell Rep. 6:553-564(2014).
RN   [29]
RP   FUNCTION IN R-LOOP PROCESSING, AND INTERACTION WITH SEM1 AND PCID2.
RX   PubMed=24896180; DOI=10.1038/nature13374;
RA   Bhatia V., Barroso S.I., Garcia-Rubio M.L., Tumini E.,
RA   Herrera-Moyano E., Aguilera A.;
RT   "BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA
RT   export factor PCID2.";
RL   Nature 511:362-365(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1519-1551 IN COMPLEX WITH
RP   RAD51.
RX   PubMed=12442171; DOI=10.1038/nature01230;
RA   Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L.,
RA   Venkitaraman A.R.;
RT   "Insights into DNA recombination from the structure of a RAD51-BRCA2
RT   complex.";
RL   Nature 420:287-293(2002).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 21-39 IN COMPLEX WITH PALB2.
RX   PubMed=19609323; DOI=10.1038/embor.2009.126;
RA   Oliver A.W., Swift S., Lord C.J., Ashworth A., Pearl L.H.;
RT   "Structural basis for recruitment of BRCA2 by PALB2.";
RL   EMBO Rep. 10:990-996(2009).
RN   [32]
RP   VARIANT OVARIAN CANCER HIS-2787, AND VARIANTS HIS-372; MET-1915 AND
RP   VAL-2466.
RX   PubMed=8665505;
RA   Takahashi H., Chiu H.-C., Bandera C.A., Behbakht K., Liu P.C.,
RA   Couch F.J., Weber B.L., LiVolsi V.A., Furusato M., Rebane B.A.,
RA   Cardonick A., Benjamin I., Morgan M.A., King S.A., Mikuta J.J.,
RA   Rubin S.C., Boyd J.;
RT   "Mutations of the BRCA2 gene in ovarian carcinomas.";
RL   Cancer Res. 56:2738-2741(1996).
RN   [33]
RP   VARIANTS HIS-372; ASP-991; SER-1147; MET-1915 AND CYS-2034.
RX   PubMed=8673091; DOI=10.1038/ng0596-123;
RA   Couch F.J., Farid L.M., Deshano M.L., Tavtigian S.V., Calzone K.,
RA   Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S.,
RA   Shattuck-Eidens D., Godwin A.K., Daly M., Radford D.M., Sedlacek S.,
RA   Rommens J., Simard J., Garber J., Merajver S., Weber B.L.;
RT   "BRCA2 germline mutations in male breast cancer cases and breast
RT   cancer families.";
RL   Nat. Genet. 13:123-125(1996).
RN   [34]
RP   VARIANT GLU-3095.
RX   PubMed=8640235; DOI=10.1038/ng0696-238;
RA   Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C.,
RA   Gumbs C., Seal S., Barfoot R., Collins N., Bignell G., Patel S.,
RA   Hamoudi R., Larsson C., Wiseman R.W., Berchuck A., Iglehart J.D.,
RA   Marks J.R., Ashworth A., Stratton M.R., Futreal P.A.;
RT   "BRCA2 mutations in primary breast and ovarian cancers.";
RL   Nat. Genet. 13:238-240(1996).
RN   [35]
RP   VARIANTS.
RX   PubMed=8640236; DOI=10.1038/ng0696-241;
RA   Teng D.H.-F., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S.,
RA   Davis T., Ha P.C., Kehrer R., Jammulapati S., Chen Q., Offit K.,
RA   Skolnick M.H., Tavtigian S.V., Jhanwar S., Swedlund B., Wong A.K.C.,
RA   Kamb A.;
RT   "Low incidence of BRCA2 mutations in breast carcinoma and other
RT   cancers.";
RL   Nat. Genet. 13:241-244(1996).
RN   [36]
RP   VARIANT BC ASN-2415.
RX   PubMed=8640237; DOI=10.1038/ng0696-245;
RA   Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y.;
RT   "Mutation analysis in the BRCA2 gene in primary breast cancers.";
RL   Nat. Genet. 13:245-247(1996).
RN   [37]
RP   VARIANT BC ASP-2089, AND VARIANT VAL-3412.
RX   PubMed=9150152;
RA   Vehmanen P., Friedman L.S., Eerola H., Sarantaus L., Pyrhoenen S.,
RA   Ponder B.A.J., Muhonen T., Nevanlinna H.;
RT   "A low proportion of BRCA2 mutations in Finnish breast cancer
RT   families.";
RL   Am. J. Hum. Genet. 60:1050-1058(1997).
RN   [38]
RP   VARIANT BC/PANCREAS CANCER TRP-554.
RX   PubMed=9654203; DOI=10.1007/s004390050738;
RA   Ganguly T., Dhulipala R., Godmilow L., Ganguly A.;
RT   "High throughput fluorescence-based conformation-sensitive gel
RT   electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an
RT   overall low incidence of BRCA2 mutations in high-risk BRCA1-negative
RT   breast cancer families.";
RL   Hum. Genet. 102:549-556(1998).
RN   [39]
RP   VARIANTS BC LEU-32; ARG-53; LEU-81; ARG-201; ALA-211; SER-222 AND
RP   THR-3118.
RX   PubMed=9609997; DOI=10.1007/s100380050035;
RA   Katagiri T., Kasumi F., Yoshimoto M., Nomizu T., Asaishi K., Abe R.,
RA   Tsuchiya A., Sugano M., Takai S., Yoneda M., Fukutomi T., Nanba K.,
RA   Makita M., Okazaki H., Hirata K., Okazaki M., Furutsuma Y.,
RA   Morishita Y., Iino Y., Karino T., Ayabe H., Hara S., Kajiwara T.,
RA   Houga S., Shimizu T., Toda M., Yamazaki Y., Uchida T., Kunitomo K.,
RA   Sonoo H., Kurebayashi J., Shimotsuma K., Nakamura Y., Miki Y.;
RT   "High proportion of missense mutations of the BRCA1 and BRCA2 genes in
RT   Japanese breast cancer families.";
RL   J. Hum. Genet. 43:42-48(1998).
RN   [40]
RP   VARIANTS OVARIAN CANCER PRO-75; HIS-2502 AND HIS-3098.
RX   PubMed=10486320; DOI=10.1086/302583;
RA   Gayther S.A., Russell P., Harrington P., Antoniou A.C., Easton D.F.,
RA   Ponder B.A.J.;
RT   "The contribution of germline BRCA1 and BRCA2 mutations to familial
RT   ovarian cancer: no evidence for other ovarian cancer-susceptibility
RT   genes.";
RL   Am. J. Hum. Genet. 65:1021-1029(1999).
RN   [41]
RP   VARIANTS HIS-289; HIS-372; ASP-991 AND VAL-3412.
RX   PubMed=10323242; DOI=10.1007/s004390050936;
RA   Li S.S.-L., Tseng H.-M., Yang T.-P., Liu C.-H., Teng S.-J.,
RA   Huang H.-W., Chen L.-M., Kao H.-W., Chen J.H., Tseng J.-N., Chen A.,
RA   Hou M.-F., Huang T.-J., Chang H.-T., Mok K.-T., Tsai J.-H.;
RT   "Molecular characterization of germline mutations in the BRCA1 and
RT   BRCA2 genes from breast cancer families in Taiwan.";
RL   Hum. Genet. 104:201-204(1999).
RN   [42]
RP   VARIANTS BC, AND VARIANTS.
RX   PubMed=9971877; DOI=10.1093/hmg/8.3.413;
RA   Wagner T.M.U., Hirtenlehner K., Shen P., Moeslinger R., Muhr D.,
RA   Fleischmann E., Concin H., Doeller W., Haid A., Lang A.H., Mayer P.,
RA   Petru E., Ropp E., Langbauer G., Kubista E., Scheiner O.,
RA   Underhill P., Mountain J., Stierer M., Zielinski C., Oefner P.;
RT   "Global sequence diversity of BRCA2: analysis of 71 breast cancer
RT   families and 95 control individuals of worldwide populations.";
RL   Hum. Mol. Genet. 8:413-423(1999).
RN   [43]
RP   VARIANT BC ARG-326, AND VARIANT ILE-2728.
RX   PubMed=10399947;
RX   DOI=10.1002/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G;
RA   Sinilnikova O.M., Egan K.M., Quinn J.L., Boutrand L., Lenoir G.M.,
RA   Stoppa-Lyonnet D., Desjardins L., Levy C., Goldgar D., Gragoudas E.S.;
RT   "Germline brca2 sequence variants in patients with ocular melanoma.";
RL   Int. J. Cancer 82:325-328(1999).
RN   [44]
RP   VARIANT HIS-372.
RX   PubMed=11062481; DOI=10.1038/81691;
RA   Healey C.S., Dunning A.M., Teare M.D., Chase D., Parker L., Burn J.,
RA   Chang-Claude J., Mannermaa A., Kataja V., Huntsman D.G.,
RA   Pharoah P.D.P., Luben R.N., Easton D.F., Ponder B.A.J.;
RT   "A common variant in BRCA2 is associated with both breast cancer risk
RT   and prenatal viability.";
RL   Nat. Genet. 26:362-364(2000).
RN   [45]
RP   VARIANTS BC MET-729; ILE-2515 AND ILE-2728, AND VARIANTS HIS-289;
RP   HIS-372; ASP-991; MET-1915 AND VAL-3412.
RX   PubMed=10978364; DOI=10.1136/jmg.37.9.e17;
RA   Plaschke J., Commer T., Jacobi C., Schackert H.K., Chang-Claude J.;
RT   "BRCA2 germline mutations among early onset breast cancer patients
RT   unselected for family history of the disease.";
RL   J. Med. Genet. 37:E17-E17(2000).
RN   [46]
RP   VARIANTS BC ASN-1179; ILE-3124 AND GLU-3196, AND VARIANT TYR-1420.
RX   PubMed=11139248;
RX   DOI=10.1002/1098-1004(2001)17:1<73::AID-HUMU12>3.3.CO;2-F;
RA   Kwiatkowska E., Teresiak M., Lamperska K.M., Karczewska A.,
RA   Breborowicz D., Stawicka M., Godlewski D., Krzyzosiak W.J.,
RA   Mackiewicz A.;
RT   "BRCA2 germline mutations in male breast cancer patients in the Polish
RT   population.";
RL   Hum. Mutat. 17:73-73(2001).
RN   [47]
RP   VARIANTS BC THR-505; TYR-1730; HIS-2135 AND CYS-2222, AND VARIANT
RP   LYS-1880.
RX   PubMed=11241844; DOI=10.1002/humu.7;
RA   Edwards S.M., Kote-Jarai Z., Hamoudi R., Eeles R.A.;
RT   "An improved high throughput heteroduplex mutation detection system
RT   for screening BRCA2 mutations-fluorescent mutation detection (F-MD).";
RL   Hum. Mutat. 17:220-232(2001).
RN   [48]
RP   VARIANT BC ARG-2722.
RX   PubMed=12145750; DOI=10.1086/342192;
RA   Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.;
RT   "BRCA2 T2722R is a deleterious allele that causes exon skipping.";
RL   Am. J. Hum. Genet. 71:625-631(2002).
RN   [49]
RP   ERRATUM.
RA   Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.;
RL   Am. J. Hum. Genet. 73:1477-1477(2002).
RN   [50]
RP   VARIANTS BC CYS-2072; CYS-2094 AND ASN-2128.
RX   PubMed=12373604; DOI=10.1038/sj.bjc.6600562;
RA   Jakubowska A., Nej K., Huzarski T., Scott R.J., Lubinski J.;
RT   "BRCA2 gene mutations in families with aggregations of breast and
RT   stomach cancers.";
RL   Br. J. Cancer 87:888-891(2002).
RN   [51]
RP   VARIANT THR-192.
RX   PubMed=12097290;
RA   Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M.,
RA   Bansal R., Hruban R.H., Kern S.E.;
RT   "Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in
RT   familial pancreatic cancer: deleterious BRCA2 mutations in 17%.";
RL   Cancer Res. 62:3789-3793(2002).
RN   [52]
RP   VARIANTS HIS-118; SER-315; ILE-1988; CYS-2842 AND SER-3300.
RX   PubMed=11948123;
RA   Hu N., Li G., Li W.-J., Wang C., Goldstein A.M., Tang Z.-Z.,
RA   Roth M.J., Dawsey S.M., Huang J., Wang Q.-H., Ding T., Giffen C.,
RA   Taylor P.R., Emmert-Buck M.R.;
RT   "Infrequent mutation in the BRCA2 gene in esophageal squamous cell
RT   carcinoma.";
RL   Clin. Cancer Res. 8:1121-1126(2002).
RN   [53]
RP   VARIANTS ALA-598; TYR-1420; CYS-2034; ILE-2728 AND THR-2951.
RX   PubMed=12215251; DOI=10.1089/10906570260199375;
RA   Deffenbaugh A.M., Frank T.S., Hoffman M., Cannon-Albright L.,
RA   Neuhausen S.L.;
RT   "Characterization of common BRCA1 and BRCA2 variants.";
RL   Genet. Test. 6:119-121(2002).
RN   [54]
RP   VARIANTS ASP-1593 AND SER-2706.
RX   PubMed=12442273; DOI=10.1002/humu.9082;
RA   Saxena S., Szabo C.I., Chopin S., Barjhoux L., Sinilnikova O.,
RA   Lenoir G., Goldgar D.E., Bhatanager D.;
RT   "BRCA1 and BRCA2 in Indian breast cancer patients.";
RL   Hum. Mutat. 20:473-474(2002).
RN   [55]
RP   VARIANT BC ASN-2729, AND VARIANT VAL-3412.
RX   PubMed=12442274; DOI=10.1002/humu.9083;
RA   Zhi X., Szabo C., Chopin S., Suter N., Wang Q.-S., Ostrander E.A.,
RA   Sinilnikova O.M., Lenoir G.M., Goldgar D., Shi Y.-R.;
RT   "BRCA1 and BRCA2 sequence variants in Chinese breast cancer
RT   families.";
RL   Hum. Mutat. 20:474-474(2002).
RN   [56]
RP   VARIANTS BC CYS-42; ARG-613; LEU-2118; LEU-2293 AND ARG-2793, AND
RP   VARIANT ILE-3374.
RX   PubMed=12442275; DOI=10.1002/humu.9084;
RA   Ruiz-Flores P., Sinilnikova O.M., Badzioch M.,
RA   Calderon-Garciduenas A.L., Chopin S., Fabrice O.,
RA   Gonzalez-Guerrero J.F., Szabo C., Lenoir G., Goldgar D.E.,
RA   Barrera-Saldana H.A.;
RT   "BRCA1 and BRCA2 mutation analysis of early-onset and familial breast
RT   cancer cases in Mexico.";
RL   Hum. Mutat. 20:474-475(2002).
RN   [57]
RP   VARIANTS BC TYR-1580 AND MET-1915.
RX   PubMed=11948477; DOI=10.1002/ijc.10289;
RA   Kwiatkowska E., Teresiak M., Breborowicz D., Mackiewicz A.;
RT   "Somatic mutations in the BRCA2 gene and high frequency of allelic
RT   loss of BRCA2 in sporadic male breast cancer.";
RL   Int. J. Cancer 98:943-945(2002).
RN   [58]
RP   INVOLVEMENT IN FANCD1.
RX   PubMed=12065746; DOI=10.1126/science.1073834;
RA   Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q.,
RA   de Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G.,
RA   Ikeda H., Fox E.A., D'Andrea A.D.;
RT   "Biallelic inactivation of BRCA2 in Fanconi anemia.";
RL   Science 297:606-609(2002).
RN   [59]
RP   VARIANTS HIS-289; HIS-372; GLY-462; ASP-991; SER-1279; TYR-1420;
RP   ASP-1771 AND VAL-2466.
RX   PubMed=12552570; DOI=10.1002/humu.9110;
RA   Hadjisavvas A., Charalambous E., Adamou A., Christodoulou C.G.,
RA   Kyriacou K.;
RT   "BRCA2 germline mutations in Cypriot patients with familial
RT   breast/ovarian cancer.";
RL   Hum. Mutat. 21:171-171(2003).
RN   [60]
RP   VARIANTS BC ILE-431; LYS-1036; ARG-1106 AND VAL-1524.
RX   PubMed=12938098; DOI=10.1002/humu.9174;
RA   Meyer P., Voigtlaender T., Bartram C.R., Klaes R.;
RT   "Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast
RT   and/or ovarian cancer families in Southern Germany.";
RL   Hum. Mutat. 22:259-259(2003).
RN   [61]
RP   VARIANTS PRO-582; PHE-1522 AND VAL-2044.
RX   PubMed=12624724; DOI=10.1007/s100380300020;
RA   Sakayori M., Kawahara M., Shiraishi K., Nomizu T., Shimada A.,
RA   Kudo T., Abe R., Ohuchi N., Takenoshita S., Kanamaru R., Ishioka C.;
RT   "Evaluation of the diagnostic accuracy of the stop codon (SC) assay
RT   for identifying protein-truncating mutations in the BRCA1and
RT   BRCA2genes in familial breast cancer.";
RL   J. Hum. Genet. 48:130-137(2003).
RN   [62]
RP   VARIANTS CYS-2034 AND GLU-3076.
RX   PubMed=12569143; DOI=10.1093/jnci/95.3.214;
RA   Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B.,
RA   Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D.,
RA   Gruetzmann R., Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P.,
RA   Bartsch D.K.;
RT   "BRCA2 germline mutations in familial pancreatic carcinoma.";
RL   J. Natl. Cancer Inst. 95:214-221(2003).
RN   [63]
RP   VARIANT FANCD1 PRO-2510.
RX   PubMed=14670928; DOI=10.1182/blood-2003-06-1970;
RA   Hirsch B., Shimamura A., Moreau L., Baldinger S., Hag-alshiekh M.,
RA   Bostrom B., Sencer S., D'Andrea A.D.;
RT   "Association of biallelic BRCA2/FANCD1 mutations with spontaneous
RT   chromosomal instability and solid tumors of childhood.";
RL   Blood 103:2554-2559(2004).
RN   [64]
RP   VARIANTS BC SER-60; ARG-405; HIS-448; GLY-462; GLY-2275; ARG-2353;
RP   LYS-2488; HIS-2723; ASN-2950; ILE-3013 AND HIS-3098, AND VARIANTS
RP   ASP-991; ALA-2856 AND VAL-3412.
RX   PubMed=15026808; DOI=10.1038/sj.bjc.6601656;
RA   Claes K., Poppe B., Coene I., De Paepe A., Messiaen L.;
RT   "BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian
RT   breast/ovarian cancer families.";
RL   Br. J. Cancer 90:1244-1251(2004).
RN   [65]
RP   VARIANTS BC ILE-64; GLY-462; ASN-1690; ASP-1771; MET-1887; MET-1915
RP   AND GLU-2456, AND VARIANTS HIS-289; HIS-372; ASP-991; SER-1279;
RP   TYR-1420; CYS-2108 AND VAL-2466.
RX   PubMed=15172753; DOI=10.1016/j.cancergencyto.2003.09.020;
RA   Hadjisavvas A., Charalambous E., Adamou A., Neuhausen S.L.,
RA   Christodoulou C.G., Kyriacou K.;
RT   "Hereditary breast and ovarian cancer in Cyprus: identification of a
RT   founder BRCA2 mutation.";
RL   Cancer Genet. Cytogenet. 151:152-156(2004).
RN   [66]
RP   VARIANT OVARIAN CANCER CYS-42, AND VARIANTS SER-3063 AND VAL-3412.
RX   PubMed=14746861; DOI=10.1016/j.ejca.2003.09.016;
RA   Malander S., Ridderheim M., Masbaeck A., Loman N., Kristoffersson U.,
RA   Olsson H., Nilbert M., Borg A.;
RT   "One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2
RT   mutations: results of a prospective study in Southern Sweden.";
RL   Eur. J. Cancer 40:422-428(2004).
RN   [67]
RP   VARIANTS BC ILE-1679; ALA-1804; LYS-1901 AND LEU-2096.
RX   PubMed=14722926; DOI=10.1002/humu.9213;
RA   Valarmathi M.T., Sawhney M., Deo S.S.V., Shukla N.K., Das S.N.;
RT   "Novel germline mutations in the BRCA1 and BRCA2 genes in Indian
RT   breast and breast-ovarian cancer families.";
RL   Hum. Mutat. 23:205-205(2004).
RN   [68]
RP   VARIANT ALA-225, AND CHARACTERIZATION OF VARIANT ALA-225.
RX   PubMed=15300854; DOI=10.1002/humu.9267;
RA   Sharp A., Pichert G., Lucassen A., Eccles D.;
RT   "RNA analysis reveals splicing mutations and loss of expression
RT   defects in MLH1 and BRCA1.";
RL   Hum. Mutat. 24:272-272(2004).
RN   [69]
RP   VARIANTS BC THR-1445; VAL-1929 AND ALA-2031, AND VARIANTS HIS-289;
RP   HIS-372; VAL-784; ASP-991 AND VAL-3412.
RX   PubMed=15365993; DOI=10.1002/humu.9275;
RA   Seo J.H., Cho D.-Y., Ahn S.-H., Yoon K.-S., Kang C.-S., Cho H.M.,
RA   Lee H.S., Choe J.J., Choi C.W., Kim B.S., Shin S.W., Kim Y.H.,
RA   Kim J.S., Son G.-S., Lee J.-B., Koo B.H.;
RT   "BRCA1 and BRCA2 germline mutations in Korean patients with sporadic
RT   breast cancer.";
RL   Hum. Mutat. 24:350-350(2004).
RN   [70]
RP   VARIANTS LEU-1172; TYR-1420; PHE-2944; ASN-2950 AND ILE-3013.
RX   PubMed=15635067; DOI=10.1136/jmg.2004.025056;
RA   Kim S.-W., Lee C.S., Fey J.V., Borgen P.I., Boyd J.;
RT   "Prevalence of BRCA2 mutations in a hospital based series of
RT   unselected breast cancer cases.";
RL   J. Med. Genet. 42:E5-E5(2005).
RN   [71]
RP   VARIANTS HIS-2336; CYS-2502; CYS-2626; PHE-2627; PRO-2653; LYS-2659;
RP   VAL-2663; ARG-2722; GLY-2723; ASP-2748 AND GLU-3095.
RX   PubMed=17924331; DOI=10.1086/521032;
RA   Easton D.F., Deffenbaugh A.M., Pruss D., Frye C., Wenstrup R.J.,
RA   Allen-Brady K., Tavtigian S.V., Monteiro A.N.A., Iversen E.S.,
RA   Couch F.J., Goldgar D.E.;
RT   "A systematic genetic assessment of 1,433 sequence variants of unknown
RT   clinical significance in the BRCA1 and BRCA2 breast cancer-
RT   predisposition genes.";
RL   Am. J. Hum. Genet. 81:873-883(2007).
RN   [72]
RP   VARIANTS FANCD1 HIS-2336 AND CYS-2626.
RX   PubMed=16825431; DOI=10.1136/jmg.2006.043257;
RA   Alter B.P., Rosenberg P.S., Brody L.C.;
RT   "Clinical and molecular features associated with biallelic mutations
RT   in FANCD1/BRCA2.";
RL   J. Med. Genet. 44:1-9(2007).
RN   [73]
RP   CHARACTERIZATION OF VARIANTS VAL-2663; GLY-2723 AND TRP-3052.
RX   PubMed=20513136; DOI=10.1002/humu.21267;
RA   Walker L.C., Whiley P.J., Couch F.J., Farrugia D.J., Healey S.,
RA   Eccles D.M., Lin F., Butler S.A., Goff S.A., Thompson B.A.,
RA   Lakhani S.R., Da Silva L.M., Tavtigian S.V., Goldgar D.E., Brown M.A.,
RA   Spurdle A.B.;
RT   "Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence
RT   variants encoding missense substitutions: implications for prediction
RT   of pathogenicity.";
RL   Hum. Mutat. 31:E1484-E1505(2010).
RN   [74]
RP   CHARACTERIZATION OF VARIANTS FANCD1 HIS-2336; PRO-2510 AND CYS-2626,
RP   CHARACTERIZATION OF VARIANTS THR-2490 AND ASN-2729, FUNCTION, AND
RP   INTERACTION WITH SEM1.
RX   PubMed=21719596; DOI=10.1182/blood-2010-12-324541;
RA   Biswas K., Das R., Alter B.P., Kuznetsov S.G., Stauffer S.,
RA   North S.L., Burkett S., Brody L.C., Meyer S., Byrd R.A., Sharan S.K.;
RT   "A comprehensive functional characterization of BRCA2 variants
RT   associated with Fanconi anemia using mouse ES cell-based assay.";
RL   Blood 118:2430-2442(2011).
RN   [75]
RP   VARIANTS LEU-606 AND TYR-1420.
RX   PubMed=26566883; DOI=10.1136/jmedgenet-2015-103179;
RA   Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G.,
RA   Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.;
RT   "Homozygous missense mutation in the LMAN2L gene segregates with
RT   intellectual disability in a large consanguineous Pakistani family.";
RL   J. Med. Genet. 53:138-144(2016).
CC   -!- FUNCTION: Involved in double-strand break repair and/or homologous
CC       recombination. Binds RAD51 and potentiates recombinational DNA
CC       repair by promoting assembly of RAD51 onto single-stranded DNA
CC       (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded
CC       DNA, enabling RAD51 to displace replication protein-A (RPA) from
CC       ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP
CC       hydrolysis. Part of a PALB2-scaffolded HR complex containing
CC       RAD51C and which is thought to play a role in DNA repair by HR.
CC       May participate in S phase checkpoint activation. Binds
CC       selectively to ssDNA, and to ssDNA in tailed duplexes and
CC       replication fork structures. May play a role in the extension step
CC       after strand invasion at replication-dependent DNA double-strand
CC       breaks; together with PALB2 is involved in both POLH localization
CC       at collapsed replication forks and DNA polymerization activity. In
CC       concert with NPM1, regulates centrosome duplication. Interacts
CC       with the TREX-2 complex (transcription and export complex 2)
CC       subunits PCID2 and SEM1, and is required to prevent R-loop-
CC       associated DNA damage and thus transcription-associated genomic
CC       instability. Silencing of BRCA2 promotes R-loop accumulation at
CC       actively transcribed genes in replicating and non-replicating
CC       cells, suggesting that BRCA2 mediates the control of R-loop
CC       associated genomic instability, independently of its known role in
CC       homologous recombination (PubMed:24896180).
CC       {ECO:0000269|PubMed:15115758, ECO:0000269|PubMed:15199141,
CC       ECO:0000269|PubMed:15671039, ECO:0000269|PubMed:18317453,
CC       ECO:0000269|PubMed:20729832, ECO:0000269|PubMed:20729858,
CC       ECO:0000269|PubMed:20729859, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:24485656,
CC       ECO:0000269|PubMed:24896180}.
CC   -!- SUBUNIT: Monomer and dimer. Interacts with RAD51; regulates RAD51
CC       recruitment and function at sites of DNA repair. Interacts with
CC       WDR16, USP11, DMC1, ROCK2 and NPM1. Interacts with SEM1; the
CC       interaction masks a nuclear export signal in BRCA2. Interacts with
CC       both nonubiquitinated and monoubiquitinated FANCD2; this complex
CC       also includes XRCC3 and phosphorylated FANCG. Part of a BRCA
CC       complex containing BRCA1, BRCA2 and PALB2. Interacts directly with
CC       PALB2 which may serve as a scaffold for a HR complex containing
CC       PALB2, BRCA2, RAD51C, RAD51 and XRCC3. Interacts with BRCA1 only
CC       in the presence of PALB2 which serves as the bridging protein.
CC       Interacts with POLH; the interaction is direct. Interacts with the
CC       TREX-2 complex subunits PCID2 and SEM1 (PubMed:24896180,
CC       PubMed:21719596). {ECO:0000269|PubMed:10373512,
CC       ECO:0000269|PubMed:12442171, ECO:0000269|PubMed:15115758,
CC       ECO:0000269|PubMed:15199141, ECO:0000269|PubMed:15314155,
CC       ECO:0000269|PubMed:15800615, ECO:0000269|PubMed:15967112,
CC       ECO:0000269|PubMed:16205630, ECO:0000269|PubMed:16793542,
CC       ECO:0000269|PubMed:18212739, ECO:0000269|PubMed:18317453,
CC       ECO:0000269|PubMed:19369211, ECO:0000269|PubMed:19609323,
CC       ECO:0000269|PubMed:20729832, ECO:0000269|PubMed:20729858,
CC       ECO:0000269|PubMed:20729859, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:24013206,
CC       ECO:0000269|PubMed:24141787, ECO:0000269|PubMed:24485656,
CC       ECO:0000269|PubMed:24896180}.
CC   -!- INTERACTION:
CC       Q14565:DMC1; NbExp=11; IntAct=EBI-79792, EBI-930865;
CC       Q9BXW9:FANCD2; NbExp=16; IntAct=EBI-79792, EBI-359343;
CC       Q9BXW9-2:FANCD2; NbExp=3; IntAct=EBI-79792, EBI-596878;
CC       Q9P0W2:HMG20B; NbExp=8; IntAct=EBI-79792, EBI-713401;
CC       Q86YC2:PALB2; NbExp=15; IntAct=EBI-79792, EBI-1222653;
CC       Q9NTI5:PDS5B; NbExp=26; IntAct=EBI-79792, EBI-1175604;
CC       Q9Y253:POLH; NbExp=6; IntAct=EBI-79792, EBI-2827270;
CC       Q06609:RAD51; NbExp=36; IntAct=EBI-79792, EBI-297202;
CC       P60896:SHFM1; NbExp=8; IntAct=EBI-79792, EBI-79819;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24013206,
CC       ECO:0000305|PubMed:21276791}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:21276791}.
CC   -!- TISSUE SPECIFICITY: Highest levels of expression in breast and
CC       thymus, with slightly lower levels in lung, ovary and spleen.
CC   -!- PTM: Phosphorylated by ATM upon irradiation-induced DNA damage.
CC       Phosphorylation by CHEK1 and CHEK2 regulates interaction with
CC       RAD51. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S
CC       phase when recombination is active, but increases as cells
CC       progress towards mitosis; this phosphorylation prevents homologous
CC       recombination-dependent repair during S phase and G2 by inhibiting
CC       RAD51 binding. {ECO:0000269|PubMed:15199141,
CC       ECO:0000269|PubMed:15800615, ECO:0000269|PubMed:18317453}.
CC   -!- PTM: Ubiquitinated in the absence of DNA damage; this does not
CC       lead to proteasomal degradation. In contrast, ubiquitination in
CC       response to DNA damage leads to proteasomal degradation.
CC       {ECO:0000269|PubMed:15314155}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal
CC       carcinoma is by far the most common type. Breast cancer is
CC       etiologically and genetically heterogeneous. Important genetic
CC       factors have been indicated by familial occurrence and bilateral
CC       involvement. Mutations at more than one locus can be involved in
CC       different families or even in the same case.
CC       {ECO:0000269|PubMed:10399947, ECO:0000269|PubMed:10978364,
CC       ECO:0000269|PubMed:11139248, ECO:0000269|PubMed:11241844,
CC       ECO:0000269|PubMed:11948477, ECO:0000269|PubMed:12145750,
CC       ECO:0000269|PubMed:12373604, ECO:0000269|PubMed:12442274,
CC       ECO:0000269|PubMed:12442275, ECO:0000269|PubMed:12938098,
CC       ECO:0000269|PubMed:14722926, ECO:0000269|PubMed:15026808,
CC       ECO:0000269|PubMed:15172753, ECO:0000269|PubMed:15365993,
CC       ECO:0000269|PubMed:16793542, ECO:0000269|PubMed:24013206,
CC       ECO:0000269|PubMed:8640237, ECO:0000269|PubMed:9150152,
CC       ECO:0000269|PubMed:9609997, ECO:0000269|PubMed:9654203,
CC       ECO:0000269|PubMed:9971877}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Pancreatic cancer 2 (PNCA2) [MIM:613347]: A malignant
CC       neoplasm of the pancreas. Tumors can arise from both the exocrine
CC       and endocrine portions of the pancreas, but 95% of them develop
CC       from the exocrine portion, including the ductal epithelium, acinar
CC       cells, connective tissue, and lymphatic tissue.
CC       {ECO:0000269|PubMed:9140390}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Breast-ovarian cancer, familial, 2 (BROVCA2)
CC       [MIM:612555]: A condition associated with familial predisposition
CC       to cancer of the breast and ovaries. Characteristic features in
CC       affected families are an early age of onset of breast cancer
CC       (often before age 50), increased chance of bilateral cancers
CC       (cancer that develop in both breasts, or both ovaries,
CC       independently), frequent occurrence of breast cancer among men,
CC       increased incidence of tumors of other specific organs, such as
CC       the prostate. Note=Disease susceptibility is associated with
CC       variations affecting the gene represented in this entry.
CC   -!- DISEASE: Fanconi anemia complementation group D1 (FANCD1)
CC       [MIM:605724]: A disorder affecting all bone marrow elements and
CC       resulting in anemia, leukopenia and thrombopenia. It is associated
CC       with cardiac, renal and limb malformations, dermal pigmentary
CC       changes, and a predisposition to the development of malignancies.
CC       At the cellular level it is associated with hypersensitivity to
CC       DNA-damaging agents, chromosomal instability (increased chromosome
CC       breakage) and defective DNA repair. {ECO:0000269|PubMed:12065746,
CC       ECO:0000269|PubMed:14670928, ECO:0000269|PubMed:16825431,
CC       ECO:0000269|PubMed:21719596}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Glioma 3 (GLM3) [MIM:613029]: Gliomas are benign or
CC       malignant central nervous system neoplasms derived from glial
CC       cells. They comprise astrocytomas and glioblastoma multiforme that
CC       are derived from astrocytes, oligodendrogliomas derived from
CC       oligodendrocytes and ependymomas derived from ependymocytes.
CC       {ECO:0000269|PubMed:15689453}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Fanconi Anemia Mutation Database;
CC       URL="http://www.rockefeller.edu/fanconi/mutate/jumpd1.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/brca2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=BRCA2 entry;
CC       URL="https://en.wikipedia.org/wiki/BRCA2";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BRCA2ID164ch13q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X95152; CAA64484.1; -; Genomic_DNA.
DR   EMBL; X95153; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95154; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95155; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95156; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95157; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95158; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95159; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95160; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95161; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95162; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95163; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95164; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95165; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95166; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95167; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95168; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95169; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95170; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95171; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95172; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95173; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95174; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95175; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95176; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95177; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; U43746; AAB07223.1; -; mRNA.
DR   EMBL; AY436640; AAQ97181.1; -; Genomic_DNA.
DR   EMBL; AL137247; CAI13195.1; -; Genomic_DNA.
DR   EMBL; AL445212; CAI13195.1; JOINED; Genomic_DNA.
DR   EMBL; AL445212; CAI40479.1; -; Genomic_DNA.
DR   EMBL; AL137247; CAI40479.1; JOINED; Genomic_DNA.
DR   EMBL; Z74739; CAA98995.2; -; Genomic_DNA.
DR   EMBL; Z73359; CAA97728.1; -; Genomic_DNA.
DR   CCDS; CCDS9344.1; -.
DR   PIR; G02334; G02334.
DR   RefSeq; NP_000050.2; NM_000059.3.
DR   UniGene; Hs.34012; -.
DR   PDB; 1N0W; X-ray; 1.70 A; B=1517-1551.
DR   PDB; 3EU7; X-ray; 2.20 A; X=21-39.
DR   PDBsum; 1N0W; -.
DR   PDBsum; 3EU7; -.
DR   ProteinModelPortal; P51587; -.
DR   SMR; P51587; -.
DR   BioGrid; 107142; 80.
DR   DIP; DIP-24214N; -.
DR   IntAct; P51587; 28.
DR   MINT; MINT-1540184; -.
DR   STRING; 9606.ENSP00000369497; -.
DR   iPTMnet; P51587; -.
DR   PhosphoSitePlus; P51587; -.
DR   BioMuta; BRCA2; -.
DR   DMDM; 14424438; -.
DR   EPD; P51587; -.
DR   PaxDb; P51587; -.
DR   PeptideAtlas; P51587; -.
DR   PRIDE; P51587; -.
DR   DNASU; 675; -.
DR   Ensembl; ENST00000380152; ENSP00000369497; ENSG00000139618.
DR   Ensembl; ENST00000544455; ENSP00000439902; ENSG00000139618.
DR   GeneID; 675; -.
DR   KEGG; hsa:675; -.
DR   UCSC; uc001uub.2; human.
DR   CTD; 675; -.
DR   DisGeNET; 675; -.
DR   GeneCards; BRCA2; -.
DR   GeneReviews; BRCA2; -.
DR   HGNC; HGNC:1101; BRCA2.
DR   HPA; HPA026815; -.
DR   MalaCards; BRCA2; -.
DR   MIM; 114480; phenotype.
DR   MIM; 600185; gene.
DR   MIM; 605724; phenotype.
DR   MIM; 612555; phenotype.
DR   MIM; 613029; phenotype.
DR   MIM; 613347; phenotype.
DR   neXtProt; NX_P51587; -.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 1331; Familial prostate cancer.
DR   Orphanet; 84; Fanconi anemia.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 227535; Hereditary breast cancer.
DR   Orphanet; 213524; Hereditary site-specific ovarian cancer syndrome.
DR   Orphanet; 319462; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations.
DR   PharmGKB; PA25412; -.
DR   eggNOG; KOG4751; Eukaryota.
DR   eggNOG; ENOG410Y06W; LUCA.
DR   HOGENOM; HOG000139693; -.
DR   HOVERGEN; HBG050731; -.
DR   InParanoid; P51587; -.
DR   KO; K08775; -.
DR   OrthoDB; EOG090300EE; -.
DR   TreeFam; TF105041; -.
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA).
DR   Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-912446; Meiotic recombination.
DR   SignaLink; P51587; -.
DR   SIGNOR; P51587; -.
DR   EvolutionaryTrace; P51587; -.
DR   GeneWiki; BRCA2; -.
DR   GenomeRNAi; 675; -.
DR   PRO; PR:P51587; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000139618; -.
DR   CleanEx; HS_BRCA2; -.
DR   ExpressionAtlas; P51587; baseline and differential.
DR   Genevisible; P51587; HS.
DR   GO; GO:0033593; C:BRCA2-MAGE-D1 complex; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0000800; C:lateral element; IDA:MGI.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:UniProtKB.
DR   GO; GO:0043015; F:gamma-tubulin binding; IPI:UniProtKB.
DR   GO; GO:0010484; F:H3 histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0010485; F:H4 histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IDA:MGI.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0051298; P:centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0031052; P:chromosome breakage; IEA:Ensembl.
DR   GO; GO:0000910; P:cytokinesis; IDA:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; TAS:Reactome.
DR   GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IDA:BHF-UCL.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IEA:Ensembl.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IDA:UniProtKB.
DR   GO; GO:0001833; P:inner cell mass cell proliferation; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0007141; P:male meiosis I; IEA:Ensembl.
DR   GO; GO:1990426; P:mitotic recombination-dependent replication fork processing; IMP:BHF-UCL.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IEA:Ensembl.
DR   GO; GO:0048478; P:replication fork protection; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0010225; P:response to UV-C; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0000732; P:strand displacement; TAS:Reactome.
DR   GO; GO:0000722; P:telomere maintenance via recombination; IEA:Ensembl.
DR   InterPro; IPR015525; BRCA2.
DR   InterPro; IPR015252; BRCA2_hlx.
DR   InterPro; IPR015187; BRCA2_OB_1.
DR   InterPro; IPR015188; BRCA2_OB_3.
DR   InterPro; IPR002093; BRCA2_repeat.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR015205; Tower_dom.
DR   PANTHER; PTHR11289; PTHR11289; 1.
DR   Pfam; PF09169; BRCA-2_helical; 1.
DR   Pfam; PF09103; BRCA-2_OB1; 1.
DR   Pfam; PF09104; BRCA-2_OB3; 1.
DR   Pfam; PF00634; BRCA2; 8.
DR   Pfam; PF09121; Tower; 1.
DR   PIRSF; PIRSF002397; BRCA2; 1.
DR   SMART; SM01341; Tower; 1.
DR   SUPFAM; SSF50249; SSF50249; 4.
DR   SUPFAM; SSF81872; SSF81872; 1.
DR   PROSITE; PS50138; BRCA2_REPEAT; 8.
PE   1: Evidence at protein level;
KW   3D-structure; Cell cycle; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; DNA damage; DNA recombination; DNA repair;
KW   DNA-binding; Fanconi anemia; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Tumor suppressor; Ubl conjugation.
FT   CHAIN         1   3418       Breast cancer type 2 susceptibility
FT                                protein.
FT                                /FTId=PRO_0000064984.
FT   REPEAT     1002   1036       BRCA2 1.
FT   REPEAT     1212   1246       BRCA2 2.
FT   REPEAT     1421   1455       BRCA2 3.
FT   REPEAT     1517   1551       BRCA2 4.
FT   REPEAT     1664   1698       BRCA2 5.
FT   REPEAT     1837   1871       BRCA2 6.
FT   REPEAT     1971   2005       BRCA2 7.
FT   REPEAT     2051   2085       BRCA2 8.
FT   REGION        1     40       Interaction with PALB2.
FT   REGION      639   1000       Interaction with NPM1.
FT                                {ECO:0000269|PubMed:21084279}.
FT   REGION     1338   1781       Interaction with POLH.
FT                                {ECO:0000269|PubMed:24485656}.
FT   REGION     1410   1595       Required for stimulation of POLH DNA
FT                                polymerization activity.
FT   REGION     2350   2545       Interaction with FANCD2.
FT   REGION     2481   2832       Interaction with SEM1.
FT                                {ECO:0000269|PubMed:10373512,
FT                                ECO:0000269|PubMed:16205630}.
FT   MOTIF      2682   2698       Nuclear export signal; masked by
FT                                interaction with SEM1.
FT                                {ECO:0000269|PubMed:24013206}.
FT   MOD_RES      70     70       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     445    445       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     492    492       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     755    755       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   MOD_RES    1970   1970       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2035   2035       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2095   2095       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3291   3291       Phosphoserine; by CDK1 and CDK2.
FT                                {ECO:0000269|PubMed:15800615}.
FT   MOD_RES    3319   3319       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3387   3387       Phosphothreonine; by CHEK1 and CHEK2.
FT                                {ECO:0000269|PubMed:18317453}.
FT   VARIANT      25     25       G -> R (in BC; abolishes interaction with
FT                                PALB2). {ECO:0000269|PubMed:16793542}.
FT                                /FTId=VAR_028167.
FT   VARIANT      31     31       W -> C (in BC; abolishes interaction with
FT                                PALB2). {ECO:0000269|PubMed:16793542}.
FT                                /FTId=VAR_028168.
FT   VARIANT      31     31       W -> R (in BC; abolishes interaction with
FT                                PALB2). {ECO:0000269|PubMed:16793542}.
FT                                /FTId=VAR_028169.
FT   VARIANT      32     32       F -> L (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005085.
FT   VARIANT      42     42       Y -> C (in BC and ovarian cancer; unknown
FT                                pathological significance;
FT                                dbSNP:rs4987046).
FT                                {ECO:0000269|PubMed:12442275,
FT                                ECO:0000269|PubMed:14746861}.
FT                                /FTId=VAR_020705.
FT   VARIANT      53     53       K -> R (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005086.
FT   VARIANT      60     60       N -> S (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_020706.
FT   VARIANT      64     64       T -> I (in BC).
FT                                {ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_032712.
FT   VARIANT      75     75       A -> P (in ovarian cancer and renal
FT                                cancer; unknown pathological
FT                                significance; dbSNP:rs28897701).
FT                                {ECO:0000269|PubMed:10486320}.
FT                                /FTId=VAR_005087.
FT   VARIANT      81     81       F -> L (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005088.
FT   VARIANT     108    108       N -> H.
FT                                /FTId=VAR_008766.
FT   VARIANT     118    118       R -> H (in one patient with esophageal
FT                                carcinoma).
FT                                {ECO:0000269|PubMed:11948123}.
FT                                /FTId=VAR_032713.
FT   VARIANT     192    192       M -> T (in one patient with pancreatic
FT                                cancer). {ECO:0000269|PubMed:12097290}.
FT                                /FTId=VAR_032714.
FT   VARIANT     201    201       P -> R (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005089.
FT   VARIANT     211    211       V -> A (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005090.
FT   VARIANT     222    222       P -> S (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005091.
FT   VARIANT     225    225       T -> A (in one patient with BC; normal
FT                                RNA expression and splicing).
FT                                {ECO:0000269|PubMed:15300854}.
FT                                /FTId=VAR_032715.
FT   VARIANT     289    289       N -> H (common polymorphism; was
FT                                originally thought to be linked to
FT                                ovarian cancer; dbSNP:rs766173).
FT                                {ECO:0000269|PubMed:10323242,
FT                                ECO:0000269|PubMed:10978364,
FT                                ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15172753,
FT                                ECO:0000269|PubMed:15365993,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_005092.
FT   VARIANT     315    315       C -> S (in one patient with esophageal
FT                                carcinoma; dbSNP:rs79483201).
FT                                {ECO:0000269|PubMed:11948123}.
FT                                /FTId=VAR_032716.
FT   VARIANT     322    322       K -> Q (in dbSNP:rs11571640).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018908.
FT   VARIANT     326    326       S -> R (in BC; dbSNP:rs28897706).
FT                                {ECO:0000269|PubMed:10399947}.
FT                                /FTId=VAR_032717.
FT   VARIANT     327    327       K -> E (in BC; unknown pathological
FT                                significance).
FT                                /FTId=VAR_008767.
FT   VARIANT     355    355       V -> L (in lung cancer).
FT                                /FTId=VAR_005093.
FT   VARIANT     372    372       N -> H (common polymorphism; may be
FT                                associated with an increased risk of
FT                                breast cancer; dbSNP:rs144848).
FT                                {ECO:0000269|PubMed:10323242,
FT                                ECO:0000269|PubMed:10978364,
FT                                ECO:0000269|PubMed:11062481,
FT                                ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15057823,
FT                                ECO:0000269|PubMed:15172753,
FT                                ECO:0000269|PubMed:15365993,
FT                                ECO:0000269|PubMed:8665505,
FT                                ECO:0000269|PubMed:8673091,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_005094.
FT   VARIANT     405    405       G -> R (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_020707.
FT   VARIANT     431    431       T -> I (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12938098}.
FT                                /FTId=VAR_020708.
FT   VARIANT     448    448       R -> H (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_020709.
FT   VARIANT     462    462       E -> G (in BC; unknown pathological
FT                                significance; dbSNP:rs56403624).
FT                                {ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_020710.
FT   VARIANT     505    505       I -> T (in BC; dbSNP:rs28897708).
FT                                {ECO:0000269|PubMed:11241844}.
FT                                /FTId=VAR_032718.
FT   VARIANT     513    513       K -> R (in dbSNP:rs28897709).
FT                                /FTId=VAR_056751.
FT   VARIANT     554    554       C -> W (in BC and pancreas cancer).
FT                                {ECO:0000269|PubMed:9654203}.
FT                                /FTId=VAR_005095.
FT   VARIANT     582    582       T -> P (in dbSNP:rs80358457).
FT                                {ECO:0000269|PubMed:12624724}.
FT                                /FTId=VAR_008768.
FT   VARIANT     598    598       T -> A (in dbSNP:rs28897710).
FT                                {ECO:0000269|PubMed:12215251}.
FT                                /FTId=VAR_020711.
FT   VARIANT     599    599       S -> F (in dbSNP:rs1046984).
FT                                {ECO:0000269|PubMed:8589730}.
FT                                /FTId=VAR_035436.
FT   VARIANT     606    606       P -> L. {ECO:0000269|PubMed:26566883}.
FT                                /FTId=VAR_076440.
FT   VARIANT     613    613       L -> R (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12442275}.
FT                                /FTId=VAR_020712.
FT   VARIANT     630    630       T -> I (in ovarian cancer).
FT                                /FTId=VAR_005096.
FT   VARIANT     707    707       D -> Y (in dbSNP:rs80358487).
FT                                /FTId=VAR_008769.
FT   VARIANT     728    728       D -> A (in BC).
FT                                /FTId=VAR_005097.
FT   VARIANT     729    729       I -> M (in BC).
FT                                {ECO:0000269|PubMed:10978364}.
FT                                /FTId=VAR_032719.
FT   VARIANT     784    784       M -> V (in dbSNP:rs11571653).
FT                                {ECO:0000269|PubMed:15365993,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_008770.
FT   VARIANT     886    886       N -> I.
FT                                /FTId=VAR_008771.
FT   VARIANT     929    929       L -> S (in dbSNP:rs2227943).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018909.
FT   VARIANT     935    935       D -> N (in BC; unknown pathological
FT                                significance; dbSNP:rs28897716).
FT                                /FTId=VAR_008772.
FT   VARIANT     976    976       S -> F (in dbSNP:rs11571656).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018910.
FT   VARIANT     982    982       I -> L (in dbSNP:rs28897717).
FT                                /FTId=VAR_056752.
FT   VARIANT     987    987       N -> I (in dbSNP:rs2227944).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018911.
FT   VARIANT     991    991       N -> D (common polymorphism;
FT                                dbSNP:rs1799944).
FT                                {ECO:0000269|PubMed:10323242,
FT                                ECO:0000269|PubMed:10978364,
FT                                ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|PubMed:15172753,
FT                                ECO:0000269|PubMed:15365993,
FT                                ECO:0000269|PubMed:8673091,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_005098.
FT   VARIANT    1036   1036       E -> K (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12938098}.
FT                                /FTId=VAR_020713.
FT   VARIANT    1106   1106       S -> R (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12938098}.
FT                                /FTId=VAR_020714.
FT   VARIANT    1147   1147       N -> S (in dbSNP:rs1799951).
FT                                {ECO:0000269|PubMed:8673091}.
FT                                /FTId=VAR_005099.
FT   VARIANT    1172   1172       S -> L (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15635067}.
FT                                /FTId=VAR_032720.
FT   VARIANT    1179   1179       S -> N (in BC).
FT                                {ECO:0000269|PubMed:11139248}.
FT                                /FTId=VAR_020715.
FT   VARIANT    1279   1279       N -> S. {ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_020716.
FT   VARIANT    1286   1286       Missing.
FT                                /FTId=VAR_008773.
FT   VARIANT    1290   1290       C -> Y (in dbSNP:rs41293485).
FT                                /FTId=VAR_008774.
FT   VARIANT    1302   1302       Missing (in BC).
FT                                /FTId=VAR_005100.
FT   VARIANT    1414   1414       T -> M (in dbSNP:rs70953664).
FT                                /FTId=VAR_008775.
FT   VARIANT    1420   1420       D -> Y (in dbSNP:rs28897727).
FT                                {ECO:0000269|PubMed:11139248,
FT                                ECO:0000269|PubMed:12215251,
FT                                ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15172753,
FT                                ECO:0000269|PubMed:15635067,
FT                                ECO:0000269|PubMed:26566883}.
FT                                /FTId=VAR_008776.
FT   VARIANT    1445   1445       K -> T (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15365993}.
FT                                /FTId=VAR_020717.
FT   VARIANT    1513   1513       D -> N.
FT                                /FTId=VAR_008777.
FT   VARIANT    1522   1522       L -> F (in one patient with BC).
FT                                {ECO:0000269|PubMed:12624724}.
FT                                /FTId=VAR_032721.
FT   VARIANT    1524   1524       F -> V (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12938098}.
FT                                /FTId=VAR_020718.
FT   VARIANT    1529   1529       G -> R (in bladder cancer;
FT                                dbSNP:rs28897728).
FT                                /FTId=VAR_005101.
FT   VARIANT    1542   1542       V -> M (in dbSNP:rs28897729).
FT                                /FTId=VAR_056753.
FT   VARIANT    1561   1561       H -> N (in dbSNP:rs2219594).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018912.
FT   VARIANT    1580   1580       C -> Y (in BC; somatic mutation).
FT                                {ECO:0000269|PubMed:11948477}.
FT                                /FTId=VAR_020719.
FT   VARIANT    1593   1593       E -> D. {ECO:0000269|PubMed:12442273}.
FT                                /FTId=VAR_008778.
FT   VARIANT    1643   1643       V -> A (in dbSNP:rs28897731).
FT                                /FTId=VAR_056754.
FT   VARIANT    1679   1679       T -> I (in BC).
FT                                {ECO:0000269|PubMed:14722926}.
FT                                /FTId=VAR_020720.
FT   VARIANT    1690   1690       K -> N (in BC).
FT                                {ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_032722.
FT   VARIANT    1730   1730       N -> Y (in BC).
FT                                {ECO:0000269|PubMed:11241844}.
FT                                /FTId=VAR_032723.
FT   VARIANT    1771   1771       G -> D (in BC; unknown pathological
FT                                significance; dbSNP:rs80358755).
FT                                {ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_008779.
FT   VARIANT    1804   1804       V -> A (in BC).
FT                                {ECO:0000269|PubMed:14722926}.
FT                                /FTId=VAR_020721.
FT   VARIANT    1805   1805       N -> S (in dbSNP:rs80358765).
FT                                /FTId=VAR_008780.
FT   VARIANT    1880   1880       N -> K (polymorphism; was originally
FT                                thought to be linked to breast cancer;
FT                                dbSNP:rs11571657).
FT                                {ECO:0000269|PubMed:11241844,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_005102.
FT   VARIANT    1887   1887       T -> M (in BC).
FT                                {ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_032724.
FT   VARIANT    1901   1901       E -> K (in BC).
FT                                {ECO:0000269|PubMed:14722926}.
FT                                /FTId=VAR_020722.
FT   VARIANT    1902   1902       D -> N (in dbSNP:rs4987048).
FT                                /FTId=VAR_008781.
FT   VARIANT    1915   1915       T -> M (may be a rare polymorphism;
FT                                somatic mutation; dbSNP:rs4987117).
FT                                {ECO:0000269|PubMed:10978364,
FT                                ECO:0000269|PubMed:11948477,
FT                                ECO:0000269|PubMed:15172753,
FT                                ECO:0000269|PubMed:8665505,
FT                                ECO:0000269|PubMed:8673091,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_005103.
FT   VARIANT    1929   1929       I -> V (in BC; unknown pathological
FT                                significance; dbSNP:rs79538375).
FT                                {ECO:0000269|PubMed:15365993}.
FT                                /FTId=VAR_020723.
FT   VARIANT    1979   1979       S -> R (in dbSNP:rs28897737).
FT                                /FTId=VAR_056755.
FT   VARIANT    1988   1988       V -> I (in one patient with esophageal
FT                                carcinoma; somatic mutation).
FT                                {ECO:0000269|PubMed:11948123}.
FT                                /FTId=VAR_032725.
FT   VARIANT    2031   2031       T -> A (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15365993}.
FT                                /FTId=VAR_020724.
FT   VARIANT    2034   2034       R -> C (in dbSNP:rs1799954).
FT                                {ECO:0000269|PubMed:12215251,
FT                                ECO:0000269|PubMed:12569143,
FT                                ECO:0000269|PubMed:8673091}.
FT                                /FTId=VAR_005104.
FT   VARIANT    2044   2044       G -> V (in one patient with BC;
FT                                dbSNP:rs56191579).
FT                                {ECO:0000269|PubMed:12624724}.
FT                                /FTId=VAR_032726.
FT   VARIANT    2072   2072       S -> C (in BC).
FT                                {ECO:0000269|PubMed:12373604}.
FT                                /FTId=VAR_020725.
FT   VARIANT    2074   2074       H -> N (in dbSNP:rs34309943).
FT                                /FTId=VAR_008782.
FT   VARIANT    2089   2089       E -> D (in BC).
FT                                {ECO:0000269|PubMed:9150152}.
FT                                /FTId=VAR_008783.
FT   VARIANT    2094   2094       Y -> C (in BC).
FT                                {ECO:0000269|PubMed:12373604}.
FT                                /FTId=VAR_020726.
FT   VARIANT    2096   2096       P -> L (in BC).
FT                                {ECO:0000269|PubMed:14722926}.
FT                                /FTId=VAR_020727.
FT   VARIANT    2108   2108       R -> C (in dbSNP:rs55794205).
FT                                {ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_032727.
FT   VARIANT    2116   2116       H -> R (in dbSNP:rs55953736).
FT                                /FTId=VAR_061563.
FT   VARIANT    2118   2118       V -> L (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12442275}.
FT                                /FTId=VAR_020728.
FT   VARIANT    2128   2128       K -> N (in BC).
FT                                {ECO:0000269|PubMed:12373604}.
FT                                /FTId=VAR_020729.
FT   VARIANT    2135   2135       N -> H (in BC).
FT                                {ECO:0000269|PubMed:11241844}.
FT                                /FTId=VAR_032728.
FT   VARIANT    2138   2138       V -> F (in dbSNP:rs11571659).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_008784.
FT   VARIANT    2162   2162       K -> R (in dbSNP:rs11571660).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018913.
FT   VARIANT    2222   2222       Y -> C (in BC).
FT                                {ECO:0000269|PubMed:11241844}.
FT                                /FTId=VAR_032729.
FT   VARIANT    2238   2238       D -> E (in dbSNP:rs28897742).
FT                                /FTId=VAR_056756.
FT   VARIANT    2274   2274       G -> V (in BC).
FT                                /FTId=VAR_005105.
FT   VARIANT    2275   2275       E -> G (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_020730.
FT   VARIANT    2293   2293       F -> L (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12442275}.
FT                                /FTId=VAR_020731.
FT   VARIANT    2336   2336       R -> H (in FANCD1; affects protein
FT                                splicing and expression; decreases
FT                                homologous recombination-mediated DNA
FT                                repair; dbSNP:rs28897743).
FT                                {ECO:0000269|PubMed:16825431,
FT                                ECO:0000269|PubMed:17924331,
FT                                ECO:0000269|PubMed:21719596}.
FT                                /FTId=VAR_032730.
FT   VARIANT    2336   2336       R -> Q (in dbSNP:rs28897743).
FT                                /FTId=VAR_056757.
FT   VARIANT    2353   2353       G -> R (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_020732.
FT   VARIANT    2415   2415       H -> N (in BC).
FT                                {ECO:0000269|PubMed:8640237}.
FT                                /FTId=VAR_005106.
FT   VARIANT    2421   2421       Q -> H (in BC).
FT                                /FTId=VAR_005107.
FT   VARIANT    2440   2440       H -> R (in dbSNP:rs4986860).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018914.
FT   VARIANT    2447   2447       N -> D (in dbSNP:rs4986859).
FT                                /FTId=VAR_056758.
FT   VARIANT    2456   2456       Q -> E (in BC).
FT                                {ECO:0000269|PubMed:15172753}.
FT                                /FTId=VAR_032731.
FT   VARIANT    2466   2466       A -> V (polymorphism; was originally
FT                                thought to be linked to ovarian cancer).
FT                                {ECO:0000269|PubMed:12552570,
FT                                ECO:0000269|PubMed:15057823,
FT                                ECO:0000269|PubMed:15172753,
FT                                ECO:0000269|PubMed:8665505,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_008785.
FT   VARIANT    2480   2480       L -> V (in dbSNP:rs80358965).
FT                                /FTId=VAR_008786.
FT   VARIANT    2488   2488       R -> K (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_020733.
FT   VARIANT    2490   2490       I -> T (polymorphism; no effect on
FT                                homologous recombination-mediated DNA
FT                                repair; no effect on interaction with
FT                                SEM1; dbSNP:rs11571707).
FT                                {ECO:0000269|PubMed:21719596,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_008787.
FT   VARIANT    2502   2502       R -> C (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17924331}.
FT                                /FTId=VAR_063911.
FT   VARIANT    2502   2502       R -> H (in ovarian cancer; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:10486320}.
FT                                /FTId=VAR_008788.
FT   VARIANT    2510   2510       L -> P (in FANCD1; hypersensitive to DNA
FT                                damage; disrupts interaction with SEM1).
FT                                {ECO:0000269|PubMed:14670928,
FT                                ECO:0000269|PubMed:21719596}.
FT                                /FTId=VAR_032732.
FT   VARIANT    2515   2515       T -> I (in BC; unknown pathological
FT                                significance; dbSNP:rs28897744).
FT                                {ECO:0000269|PubMed:10978364}.
FT                                /FTId=VAR_008789.
FT   VARIANT    2626   2626       W -> C (in FANCD1; hypersensitive to DNA
FT                                damage; no effect on interaction with
FT                                SEM1). {ECO:0000269|PubMed:16825431,
FT                                ECO:0000269|PubMed:17924331,
FT                                ECO:0000269|PubMed:21719596}.
FT                                /FTId=VAR_032733.
FT   VARIANT    2627   2627       I -> F (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17924331}.
FT                                /FTId=VAR_063912.
FT   VARIANT    2653   2653       L -> P (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17924331}.
FT                                /FTId=VAR_063913.
FT   VARIANT    2659   2659       R -> K (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17924331}.
FT                                /FTId=VAR_063914.
FT   VARIANT    2663   2663       E -> V (could be associated with cancer
FT                                susceptibility; major splicing aberration
FT                                identified with this mutant;
FT                                multifactorial likelihood analysis
FT                                provides evidence for pathogenicity).
FT                                {ECO:0000269|PubMed:17924331,
FT                                ECO:0000269|PubMed:20513136}.
FT                                /FTId=VAR_063915.
FT   VARIANT    2686   2686       L -> P (in dbSNP:rs28897746).
FT                                /FTId=VAR_056759.
FT   VARIANT    2706   2706       N -> S. {ECO:0000269|PubMed:12442273}.
FT                                /FTId=VAR_020734.
FT   VARIANT    2722   2722       T -> R (in BC).
FT                                {ECO:0000269|PubMed:12145750,
FT                                ECO:0000269|PubMed:17924331}.
FT                                /FTId=VAR_018661.
FT   VARIANT    2723   2723       D -> G (could be associated with cancer
FT                                susceptibility; has abrogated function
FT                                consistent with pathogenicity; major
FT                                splicing aberration identified with this
FT                                mutant). {ECO:0000269|PubMed:17924331,
FT                                ECO:0000269|PubMed:20513136}.
FT                                /FTId=VAR_063916.
FT   VARIANT    2723   2723       D -> H (in BC; unknown pathological
FT                                significance; disrupts interaction with
FT                                SEM1 promoting interaction with XPO1 and
FT                                BRCA2 cytoplasmic localization; in
FT                                heterozygous state promotes RAD51
FT                                cytoplasmic localization).
FT                                {ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|PubMed:24013206}.
FT                                /FTId=VAR_020735.
FT   VARIANT    2728   2728       V -> I (in BC; dbSNP:rs28897749).
FT                                {ECO:0000269|PubMed:10399947,
FT                                ECO:0000269|PubMed:10978364,
FT                                ECO:0000269|PubMed:12215251}.
FT                                /FTId=VAR_020736.
FT   VARIANT    2729   2729       K -> N (in BC; unknown pathological
FT                                significance; no effect on homologous
FT                                recombination-mediated DNA repair; no
FT                                effect on interaction with SEM1;
FT                                dbSNP:rs80359065).
FT                                {ECO:0000269|PubMed:12442274,
FT                                ECO:0000269|PubMed:21719596}.
FT                                /FTId=VAR_020737.
FT   VARIANT    2748   2748       G -> D (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17924331}.
FT                                /FTId=VAR_063917.
FT   VARIANT    2787   2787       R -> H (in ovarian cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:8665505}.
FT                                /FTId=VAR_008790.
FT   VARIANT    2792   2792       L -> P (in dbSNP:rs28897751).
FT                                /FTId=VAR_056760.
FT   VARIANT    2793   2793       G -> R (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:12442275}.
FT                                /FTId=VAR_020738.
FT   VARIANT    2835   2835       S -> P (in dbSNP:rs11571746).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018915.
FT   VARIANT    2842   2842       R -> C (in one patient with esophageal
FT                                carcinoma; somatic mutation).
FT                                {ECO:0000269|PubMed:11948123}.
FT                                /FTId=VAR_032734.
FT   VARIANT    2856   2856       E -> A (in dbSNP:rs11571747).
FT                                {ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018916.
FT   VARIANT    2944   2944       I -> F (in dbSNP:rs4987047).
FT                                {ECO:0000269|PubMed:15635067,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_008791.
FT   VARIANT    2950   2950       K -> N (in BC; unknown pathological
FT                                significance; dbSNP:rs28897754).
FT                                {ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|PubMed:15635067}.
FT                                /FTId=VAR_020739.
FT   VARIANT    2951   2951       A -> T (in dbSNP:rs11571769).
FT                                {ECO:0000269|PubMed:12215251,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_008792.
FT   VARIANT    2969   2969       V -> M (in dbSNP:rs59004709).
FT                                /FTId=VAR_008793.
FT   VARIANT    3013   3013       T -> I (in BC; unknown pathological
FT                                significance; dbSNP:rs28897755).
FT                                {ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|PubMed:15635067}.
FT                                /FTId=VAR_020740.
FT   VARIANT    3052   3052       R -> W (could be associated with cancer
FT                                susceptibility; has abrogated function
FT                                consistent with pathogenicity;
FT                                multifactorial likelihood analysis
FT                                provides evidence for pathogenicity).
FT                                {ECO:0000269|PubMed:20513136}.
FT                                /FTId=VAR_063918.
FT   VARIANT    3063   3063       P -> S (in a patient with ovarian cancer;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:14746861}.
FT                                /FTId=VAR_020741.
FT   VARIANT    3076   3076       G -> E. {ECO:0000269|PubMed:12569143}.
FT                                /FTId=VAR_020742.
FT   VARIANT    3095   3095       D -> E (in BC; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17924331,
FT                                ECO:0000269|PubMed:8640235}.
FT                                /FTId=VAR_005108.
FT   VARIANT    3098   3098       Y -> H (in BC and ovarian cancer; unknown
FT                                pathological significance;
FT                                dbSNP:rs41293521).
FT                                {ECO:0000269|PubMed:10486320,
FT                                ECO:0000269|PubMed:15026808}.
FT                                /FTId=VAR_008794.
FT   VARIANT    3101   3101       L -> R (in dbSNP:rs28897758).
FT                                /FTId=VAR_056761.
FT   VARIANT    3103   3103       I -> M (in melanoma).
FT                                /FTId=VAR_005109.
FT   VARIANT    3118   3118       M -> T (in BC).
FT                                {ECO:0000269|PubMed:9609997}.
FT                                /FTId=VAR_005110.
FT   VARIANT    3124   3124       N -> I (in BC).
FT                                {ECO:0000269|PubMed:11139248}.
FT                                /FTId=VAR_020743.
FT   VARIANT    3196   3196       K -> E (in BC; dbSNP:rs80359228).
FT                                {ECO:0000269|PubMed:11139248}.
FT                                /FTId=VAR_020744.
FT   VARIANT    3244   3244       V -> I (in dbSNP:rs11571831).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018917.
FT   VARIANT    3257   3257       K -> R.
FT                                /FTId=VAR_008795.
FT   VARIANT    3276   3276       R -> S.
FT                                /FTId=VAR_008796.
FT   VARIANT    3300   3300       P -> S (in one patient with esophageal
FT                                carcinoma).
FT                                {ECO:0000269|PubMed:11948123}.
FT                                /FTId=VAR_032735.
FT   VARIANT    3357   3357       T -> R (in BC).
FT                                /FTId=VAR_005111.
FT   VARIANT    3374   3374       T -> I (in dbSNP:rs56309455).
FT                                {ECO:0000269|PubMed:12442275}.
FT                                /FTId=VAR_020745.
FT   VARIANT    3412   3412       I -> V (polymorphism; was originally
FT                                thought to be associated with breast
FT                                cancer; dbSNP:rs1801426).
FT                                {ECO:0000269|PubMed:10323242,
FT                                ECO:0000269|PubMed:10978364,
FT                                ECO:0000269|PubMed:12442274,
FT                                ECO:0000269|PubMed:14746861,
FT                                ECO:0000269|PubMed:15026808,
FT                                ECO:0000269|PubMed:15365993,
FT                                ECO:0000269|PubMed:9150152,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_005112.
FT   MUTAGEN    2725   2725       W->A: Disrupts interaction with SEM1.
FT                                {ECO:0000269|PubMed:24013206}.
FT   MUTAGEN    3291   3291       S->E: Impaired interaction with RAD51.
FT                                {ECO:0000269|PubMed:15800615}.
FT   MUTAGEN    3387   3387       T->A: Loss of phosphorylation by CHEK1
FT                                and CHEK2 (in vitro).
FT                                {ECO:0000269|PubMed:18317453}.
FT   CONFLICT    758    758       S -> N (in Ref. 1; CAA64484).
FT                                {ECO:0000305}.
FT   CONFLICT   1761   1762       GY -> RI (in Ref. 1; CAA64484).
FT                                {ECO:0000305}.
FT   CONFLICT   1767   1767       K -> N (in Ref. 1; CAA64484).
FT                                {ECO:0000305}.
FT   CONFLICT   2536   2536       S -> P (in Ref. 4; CAA98995).
FT                                {ECO:0000305}.
FT   CONFLICT   3216   3216       L -> LVS (in Ref. 4; CAA97728).
FT                                {ECO:0000305}.
FT   HELIX        31     35       {ECO:0000244|PDB:3EU7}.
FT   HELIX      1520   1522       {ECO:0000244|PDB:1N0W}.
FT   HELIX      1536   1541       {ECO:0000244|PDB:1N0W}.
FT   TURN       1542   1546       {ECO:0000244|PDB:1N0W}.
SQ   SEQUENCE   3418 AA;  384202 MW;  6A0B3B7B332153EB CRC64;
     MPIGSKERPT FFEIFKTRCN KADLGPISLN WFEELSSEAP PYNSEPAEES EHKNNNYEPN
     LFKTPQRKPS YNQLASTPII FKEQGLTLPL YQSPVKELDK FKLDLGRNVP NSRHKSLRTV
     KTKMDQADDV SCPLLNSCLS ESPVVLQCTH VTPQRDKSVV CGSLFHTPKF VKGRQTPKHI
     SESLGAEVDP DMSWSSSLAT PPTLSSTVLI VRNEEASETV FPHDTTANVK SYFSNHDESL
     KKNDRFIASV TDSENTNQRE AASHGFGKTS GNSFKVNSCK DHIGKSMPNV LEDEVYETVV
     DTSEEDSFSL CFSKCRTKNL QKVRTSKTRK KIFHEANADE CEKSKNQVKE KYSFVSEVEP
     NDTDPLDSNV ANQKPFESGS DKISKEVVPS LACEWSQLTL SGLNGAQMEK IPLLHISSCD
     QNISEKDLLD TENKRKKDFL TSENSLPRIS SLPKSEKPLN EETVVNKRDE EQHLESHTDC
     ILAVKQAISG TSPVASSFQG IKKSIFRIRE SPKETFNASF SGHMTDPNFK KETEASESGL
     EIHTVCSQKE DSLCPNLIDN GSWPATTTQN SVALKNAGLI STLKKKTNKF IYAIHDETSY
     KGKKIPKDQK SELINCSAQF EANAFEAPLT FANADSGLLH SSVKRSCSQN DSEEPTLSLT
     SSFGTILRKC SRNETCSNNT VISQDLDYKE AKCNKEKLQL FITPEADSLS CLQEGQCEND
     PKSKKVSDIK EEVLAAACHP VQHSKVEYSD TDFQSQKSLL YDHENASTLI LTPTSKDVLS
     NLVMISRGKE SYKMSDKLKG NNYESDVELT KNIPMEKNQD VCALNENYKN VELLPPEKYM
     RVASPSRKVQ FNQNTNLRVI QKNQEETTSI SKITVNPDSE ELFSDNENNF VFQVANERNN
     LALGNTKELH ETDLTCVNEP IFKNSTMVLY GDTGDKQATQ VSIKKDLVYV LAEENKNSVK
     QHIKMTLGQD LKSDISLNID KIPEKNNDYM NKWAGLLGPI SNHSFGGSFR TASNKEIKLS
     EHNIKKSKMF FKDIEEQYPT SLACVEIVNT LALDNQKKLS KPQSINTVSA HLQSSVVVSD
     CKNSHITPQM LFSKQDFNSN HNLTPSQKAE ITELSTILEE SGSQFEFTQF RKPSYILQKS
     TFEVPENQMT ILKTTSEECR DADLHVIMNA PSIGQVDSSK QFEGTVEIKR KFAGLLKNDC
     NKSASGYLTD ENEVGFRGFY SAHGTKLNVS TEALQKAVKL FSDIENISEE TSAEVHPISL
     SSSKCHDSVV SMFKIENHND KTVSEKNNKC QLILQNNIEM TTGTFVEEIT ENYKRNTENE
     DNKYTAASRN SHNLEFDGSD SSKNDTVCIH KDETDLLFTD QHNICLKLSG QFMKEGNTQI
     KEDLSDLTFL EVAKAQEACH GNTSNKEQLT ATKTEQNIKD FETSDTFFQT ASGKNISVAK
     ESFNKIVNFF DQKPEELHNF SLNSELHSDI RKNKMDILSY EETDIVKHKI LKESVPVGTG
     NQLVTFQGQP ERDEKIKEPT LLGFHTASGK KVKIAKESLD KVKNLFDEKE QGTSEITSFS
     HQWAKTLKYR EACKDLELAC ETIEITAAPK CKEMQNSLNN DKNLVSIETV VPPKLLSDNL
     CRQTENLKTS KSIFLKVKVH ENVEKETAKS PATCYTNQSP YSVIENSALA FYTSCSRKTS
     VSQTSLLEAK KWLREGIFDG QPERINTADY VGNYLYENNS NSTIAENDKN HLSEKQDTYL
     SNSSMSNSYS YHSDEVYNDS GYLSKNKLDS GIEPVLKNVE DQKNTSFSKV ISNVKDANAY
     PQTVNEDICV EELVTSSSPC KNKNAAIKLS ISNSNNFEVG PPAFRIASGK IVCVSHETIK
     KVKDIFTDSF SKVIKENNEN KSKICQTKIM AGCYEALDDS EDILHNSLDN DECSTHSHKV
     FADIQSEEIL QHNQNMSGLE KVSKISPCDV SLETSDICKC SIGKLHKSVS SANTCGIFST
     ASGKSVQVSD ASLQNARQVF SEIEDSTKQV FSKVLFKSNE HSDQLTREEN TAIRTPEHLI
     SQKGFSYNVV NSSAFSGFST ASGKQVSILE SSLHKVKGVL EEFDLIRTEH SLHYSPTSRQ
     NVSKILPRVD KRNPEHCVNS EMEKTCSKEF KLSNNLNVEG GSSENNHSIK VSPYLSQFQQ
     DKQQLVLGTK VSLVENIHVL GKEQASPKNV KMEIGKTETF SDVPVKTNIE VCSTYSKDSE
     NYFETEAVEI AKAFMEDDEL TDSKLPSHAT HSLFTCPENE EMVLSNSRIG KRRGEPLILV
     GEPSIKRNLL NEFDRIIENQ EKSLKASKST PDGTIKDRRL FMHHVSLEPI TCVPFRTTKE
     RQEIQNPNFT APGQEFLSKS HLYEHLTLEK SSSNLAVSGH PFYQVSATRN EKMRHLITTG
     RPTKVFVPPF KTKSHFHRVE QCVRNINLEE NRQKQNIDGH GSDDSKNKIN DNEIHQFNKN
     NSNQAAAVTF TKCEEEPLDL ITSLQNARDI QDMRIKKKQR QRVFPQPGSL YLAKTSTLPR
     ISLKAAVGGQ VPSACSHKQL YTYGVSKHCI KINSKNAESF QFHTEDYFGK ESLWTGKGIQ
     LADGGWLIPS NDGKAGKEEF YRALCDTPGV DPKLISRIWV YNHYRWIIWK LAAMECAFPK
     EFANRCLSPE RVLLQLKYRY DTEIDRSRRS AIKKIMERDD TAAKTLVLCV SDIISLSANI
     SETSSNKTSS ADTQKVAIIE LTDGWYAVKA QLDPPLLAVL KNGRLTVGQK IILHGAELVG
     SPDACTPLEA PESLMLKISA NSTRPARWYT KLGFFPDPRP FPLPLSSLFS DGGNVGCVDV
     IIQRAYPIQW MEKTSSGLYI FRNEREEEKE AAKYVEAQQK RLEALFTKIQ EEFEEHEENT
     TKPYLPSRAL TRQQVRALQD GAELYEAVKN AADPAYLEGY FSEEQLRALN NHRQMLNDKK
     QAQIQLEIRK AMESAEQKEQ GLSRDVTTVW KLRIVSYSKK EKDSVILSIW RPSSDLYSLL
     TEGKRYRIYH LATSKSKSKS ERANIQLAAT KKTQYQQLPV SDEILFQIYQ PREPLHFSKF
     LDPDFQPSCS EVDLIGFVVS VVKKTGLAPF VYLSDECYNL LAIKFWIDLN EDIIKPHMLI
     AASNLQWRPE SKSGLLTLFA GDFSVFSASP KEGHFQETFN KMKNTVENID ILCNEAENKL
     MHILHANDPK WSTPTKDCTS GPYTAQIIPG TGNKLLMSSP NCEIYYQSPL SLCMAKRKSV
     STPVSAQMTS KSCKGEKEID DQKNCKKRRA LDFLSRLPLP PPVSPICTFV SPAAQKAFQP
     PRSCGTKYET PIKKKELNSP QMTPFKKFNE ISLLESNSIA DEELALINTQ ALLSGSTGEK
     QFISVSESTR TAPTSSEDYL RLKRRCTTSL IKEQESSQAS TEECEKNKQD TITTKKYI
//
